



About BPAL/M: A Regimen to Treat DR-TB




BPAL/M is a six-month, all-oral treatment regimen composed of bedaquiline, pretomanid, linezolid, with or without moxifloxacin is a therapy for people with drug-resistant tuberculosis (DR-TB). The World Health Organization (WHO) now prioritizes the BPAL/M regimen over an older regimen that lasted 9-18 months or longer to treat people with DR-TB.

HOW DOES BPAL/M COMPARE TO OLDER REGIMENS?

Duration: 9-18 months or 2+ years



Pill Burden: 14,000+ over the course of treatment



6 months



Fewer than 850 over the course of treatment



BPAL/M has the power to help save lives and accelerate efforts #endTB



Going from about a
50%
successful cure rate
using the old regimen



To approximately
90%
successful cure rate
using BPAL/M

BPAL/M can save costs compared to longer, more burdensome regimens

Switching to BPAL/M could save national governments about

740 million dollars annually



The cost per person completing treatment dropped more than

50% in three diverse countries



Older treatment options for DR-TB range from \$2000-\$8000 per course. It's roughly

600 USD for BPAL-based regimens


Hear from DR-TB survivors who were treated with BPAL/M



HEAR FROM
MAPALESA



HEAR FROM
MARIIA



HEAR FROM
PANGANA



HEAR FROM
ANNA CHRISTINA

